Sun Pharma's Bold USD 11.75 Billion Bet: Expanding Horizons Amid Global Turbulence

Sun Pharmaceutical Industries' acquisition of Organon & Co for USD 11.75 billion is a strategic move to enter the Chinese market and expand in biosimilars. Despite the significant debt required, Executive Chairman Dilip Shanghvi emphasizes risk-taking amid global challenges, aiming for accelerated growth and strategic global presence.

Sun Pharmaceutical Industries has announced its acquisition of US-based Organon & Co at an enterprise valuation of USD 11.75 billion, marking a significant move in the pharmaceutical sector.

In a media conference held in Mumbai, Executive Chairman Dilip Shanghvi expressed mixed feelings, citing the transaction's size and the debt required to fund it. While Sun Pharma traditionally avoids high debt, the opportunity to tap into new markets, especially China, and enter the global biosimilars business was deemed too lucrative to pass.

Shanghvi reassured stakeholders about Sun Pharma's capability to manage debt, drawing parallels with the past acquisition of Ranbaxy. The strategy involves utilizing USD 2-2.5 billion in cash alongside committed bank financing for the remaining amount.